BlackRock, Inc. 13D and 13G filings for TScan Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX |
BLACKROCK INC BLK |
4,633,276 9.500% |
0 (Unchanged) |
Filing |
| 2024-10-21 4:11 pm Purchase |
2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX |
BLACKROCK INC BLK |
4,633,276 9.500% |
3,366,088 (+265.63%) |
Filing |
| 2023-06-08 1:25 pm Sale |
2023-05-31 | 13G | TScan Therapeutics, Inc. TCRX |
BLACKROCK INC BLK |
1,267,188 3.000% |
-246,758 (-16.30%) |
Filing |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
BLACKROCK INC BLK |
1,513,946 8.000% |
15,408 (+1.03%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
BLACKROCK INC BLK |
1,498,538 8.000% |
1,498,538 (New Position) |
Filing |